Background-Whether heart failure (HF) increases the risk of venous thromboembolism (VTE)
Heart failure (HF) is a common, costly, and potentially fatal syndrome. In developed countries, approximately 2% of the adult population suffers from HF; this rate increases to 6% to 10% in those aged 65 years.
1 Hospitalized HF is associated with an increased risk of venous thromboembolism (VTE) as a result of vascular abnormalities, increased coagulability, and impaired blood flow. 2 In the absence of thromboprophylaxis, the incidence of VTE has been reported to range from approximately 4% to 26% in patients with decompensated HF. 3 A recent study showed that HF increases the near-term risk for pulmonary embolism (PE) not associated with diagnosed peripheral deep vein thrombosis (DVT), 4 In patients with PE, recurrent VTE and right ventricular dysfunction have both been associated with elevated levels of N-terminal probrain natriuretic peptide (NT-proBNP). 5, 6 However, the relationship between HF severity and risk of VTE is not well established.
Several clinical trials have demonstrated that the risk of VTE in patients with HF can be reduced with thromboprophylaxis, 7-10 and the American College of Chest Physicians clinical practice guidelines recommend the use of unfractionated heparin, low-molecular-weight heparin, or fondaparinux in acutely ill medical patients with HF at risk of thrombosis. 11 However, despite these guidelines, there is evidence that thromboprophylaxis is underused in this patient group, and there is uncertainty about which patients with HF should receive thromboprophylaxis.
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An analysis of US registry data has shown that pharmacologic VTE prophylaxis is provided to less than one-third of eligible patients hospitalized with New York Heart Association (NYHA)
class III or IV HF. 16 Therefore, there is a need to identify patients with hospitalized HF who are at particularly high risk of VTE to facilitate the provision of optimal thromboprophylaxis.
MAGELLAN was a multicenter, randomized, double-blind phase III study in hospitalized, acutely ill patients, in which rivaroxaban (35±4 days) was compared with brain natriuretic peptide (NT-proBNP). 5, 6 However, the relationship between HF F se e eve ve v ri ri rity ty ty a a and nd nd isk of VTE is not well established.
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Methods

Patients and Study Design
The study design of MAGELLAN and the inclusion and exclusion criteria have been reported previously. 18 In brief, patients who were 40 years of age and who were hospitalized for an acute medical illness with risk factors for VTE were randomized to receive either subcutaneous enoxaparin 40 mg once daily for 10 4 days followed by placebo up to Day 35, or oral rivaroxaban 10 mg once daily for 35 4 days. The study was approved by an institutional review committee and all patients gave informed consent.
The primary efficacy endpoints were the composite of asymptomatic proximal DVT, symptomatic DVT, symptomatic non-fatal PE, and VTE-related death up to Day 10 and Day 35.
The principal safety outcome was clinically relevant bleeding (the composite of treatmentemergent major bleeding and non-major clinically relevant bleeding up to Day 10 and Day 35).
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Laboratory Parameters
In patients categorized as having HF, plasma was drawn at screening, Day 10, and Day 35, and stored at -80°C. Measurement of NT-proBNP concentration (pg/mL) was carried out subsequently by a central laboratory using an enzyme immunoassay for the quantitative determination of NT-proBNP levels (Biomedica, Vienna, Austria) as described previously. 21 Patients with HF were stratified into quartiles according to baseline NT-proBNP concentration (quartile 1: <765 pg/mL; quartile 2: 767-1904 pg/mL; quartile 3: 1906-5034 pg/mL; quartile 4:
>5038 pg/mL) for comparative analysis of the primary efficacy, principal safety, and major bleeding outcomes. NT-proBNP concentrations were not measured in patients who were not hospitalized for HF.
In all patients, D-dimer concentration was determined at baseline, Day 10, and Day 35 using the STA-Liatest D-DI (Diagnostica Stago, Asnières-sur-Seine, France) assay (upper limit of normal 0.5 g/mL). Prothrombin time (PT) was measured using the STA Neoplastine CI Plus assay (Diagnostica Stago). The prothrombinase-induced clotting time (PiCT) assay (Diagnostica Stago) was used to extrapolate rivaroxaban plasma concentration. PT and PiCT were measured at baseline, Day 1, Day 10, and Day 35.
Statistical Analysis
Patients with HF were a predefined subgroup. Measurement of NT-proBNP and D-dimer concentration was planned for analytic purposes. A multivariable analysis of the primary efficacy endpoint for two prespecified time periods (Day 1-10 and Day 1 35; Day 1 being the day of randomization) was conducted in HF patients. The multivariable analysis included treatment group and NT-proBNP concentration at baseline, and applied a stepwise variable selection (using an entry level of 30%) for additional covariates. Analyses up to Day 10 and up hospitalized for HF.
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Cumulative rates of symptomatic VTE and cardiovascular death up to Day 90+7 were analyzed for non-HF patients and for HF patients by NT-proBNP quartile using a Kaplan-Meier curve for the cumulative event rate for each quartile group. A log-rank test was used to compare the distribution between quartiles 1 and 4 and to calculate P-values for differences between quartiles.
Cumulative rates and bleeding outcomes up to Day 10 and Day 35 were recorded in the safety population, which included all patients who had received at least one dose of study medication. All other analyses were performed in the modified intention-to-treat population, which included patients valid for the safety population who had an adequate assessment of VTE.
Results
Patients
A total of 8101 patients were randomized in the MAGELLAN study. Of the 7998 patients included in the safety population, 2593 (32%) were diagnosed with HF; 1773 patients had Cumulative rates of symptomatic VTE and cardiovascular death up to D Da ay ay 9 9 90+ 0+ +7 7 7 we we were re r analyzed for non-HF patients and for HF patients by NT-proBNP quartile using a Kaplan-Meier cu urv rv ve e fo fo for r th th the e cumu mu mula lative event rate for each qua ar r rti ti t le e group. A log-g-g ra r nk nk k t t te es est was used to compare h h he d distribution on b b bet twe ween en nua ua uart rt rti il ile es s 1 1 an and d 4 4 an n nd d to c c ca al lcu ula la late te P P P-v v val alu ue ues s fo for r r d di iff ffe er ere en ence ce es s s be be betw tw we ee een n qu quar ar a ti ti tile le les. s. Tables 1 to 3 . History of atrial fibrillation, hypertension, and coronary artery disease occurred at a higher incidence in patients with HF than in those without HF. Ischemic cardiomyopathy was the most frequent etiology for HF in the index hospitalization, followed by hypertensive cardiomyopathy ( Table 1) . Patients with HF had more co-medication use with beta-blocking agents, angiotensin-converting-enzyme inhibitors, or organic nitrates used for the treatment of this condition ( Table 2 ). The highest NT-proBNP levels were associated with more severe renal impairment ( Table 3) .
Heart Failure Severity and Venous Thromboembolic Risk
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The multivariable analysis in hospitalized HF patients indicated that NT-proBNP level was associated with VTE risk up to Day 10 (P=0.0173) but not up to Day 35 (P=0.8208) ( Table   5 ). The multivariable analysis also identified D-dimer (P=0.0047) and baseline high sensitivity C-reactive protein (P=0.5329) as being associated with VTE risk up to Day 35. Treatment group, body mass index, and creatinine clearance were not associated with VTE risk at either time point (Table 5 ).
In the HF group, incidence rates for the primary efficacy endpoint up to Day 10 and Day 35 were, however, similar when the severity of HF was classified as NYHA class III and class IV ( Table 6 ).
Cumulative Incidence of Symptomatic Venous Thromboembolism and Cardiovascular
Death
The Kaplan-Meier curve of symptomatic VTE indicates that, from an early time point, HF patients with the highest NT-proBNP levels (quartile 4) are at increased risk compared with those in quartile 1 and that this risk continues to increase over time (P=0.0248 for difference in cumulative incidence) ( Figure 3A) . Likewise, the cumulative incidence of cardiovascular death increases more rapidly in the group of the fourth NT-proBNP quartile compared with the group of the first quartile (P<0.001 for difference in cumulative incidence) ( Figure 3B ).
Heart Failure Severity and Risk of Bleeding
Up to both Day 10 and Day 35, there was a numerical increase in clinically relevant bleeding as NT-proBNP concentration increased ( Table 7) . Major bleeding occurred at a low rate in patients without HF and across HF quartiles ( Table 7) Table 6 ).
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The relative risk of clinically relevant bleeding was significantly higher up to Day 10 for HF patients with the highest NT-proBNP compared with non-HF patients. No significant difference was seen up to Day 35 (Figures 4A and 4B) .
Treatment Differences
In patients with severe HF with high NT-proBNP or NYHA class IV, the incidence rates of the primary efficacy endpoint were lower in the rivaroxaban group than in the enoxaparin/placebo group (Tables 4 and 6, respectively). Up to both Day 10 and Day 35, there was an association between VTE risk and NT-proBNP concentration in the enoxaparin/placebo group (P=0.0060
and P=0.0305, respectively) but not in the rivaroxaban group at either time point (Table 4) .
Likewise, in the enoxaparin/placebo group, the relative risk of VTE was significantly higher for HF patients in quartiles 3 and 4 up to Day 10 and quartile 3 up to Day 35 (included the placeboonly phase) compared with non-HF patients ( Figures 1A and 1B) , whereas no differences in the relative risk of VTE were seen in the rivaroxaban group between HF and non-HF patients at either time point (Figures 1A and 1B) .
D-dimer levels were also lower, although not significantly, in HF patients with the highest NT-proBNP levels in the rivaroxaban group compared with the enoxaparin/placebo group up to Day 35 (included the placebo-only phase) ( Figure 2B ).
Of note, rivaroxaban plasma concentrations, extrapolated using the PiCT assay, were not affected by the presence or severity of HF but there was a trend towards prolonged PT as severity increased (Table 3) .
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A positive correlation was seen between NT-proBNP concentration and D-dimer concentration, another marker that has recently been shown to predict VTE risk in acutely ill medical patients. 26 This difference was most marked for the patients with more severe HF, who had noticeably higher D-dimer levels than patients without HF at each time point tested. The National Registry, which included HF patients aged 65 years, higher BNP level els s we w w re re re n n not ot ot associated with an increase in the risk of thromboembolism.
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Kaplan-Meier curves of symptomatic VTE and cardiovascular death further support the finding that patients with severe HF are a high-risk group. For both symptomatic venous thromboembolic events and cardiovascular death, the curve for the highest NT-proBNP concentrations separates early from the curve for the quartile 1 HF group and the cumulative rate continues to increase throughout the study duration (up to Day 90+7). Data from the Acute Decompensated Heart Failure National Registry support these findings; each 30% increase in BNP was associated with an increased risk of death and myocardial infarction. The significant association between VTE risk and HF severity that was observed in the overall and enoxaparin/placebo groups was not seen in the extended-duration rivaroxaban group, suggesting that rivaroxaban may reduce the risk of VTE in patients with more severe HF. This finding is supported by the lower levels of D-dimer concentration with rivaroxaban compared with enoxaparin/placebo in patients with severe HF; however, the incidence of clinically relevant bleeding with rivaroxaban was higher across all quartiles This analysis has some limitations. Although HF was a predefined subgroup, the analysis periods were predefined, and the measurement of NT-proBNP was planned for analytic purposes, the details of this specific analysis were not prespecified. Given the exploratory nature of these analyses, no adjustments to significance levels were made to account for multiple concentration increased, and the risk of bleeding was higher in patients with the mo mo mos st s sev v ever er ere e e H HF han in patients without HF up to Day 10. It is possible that the increase in risk of bleeding could be e a a a r res es es l ul ult t t of of of oth h her er er p patient factors, such as decre e eas as a e ed renal functio o on n an nd/ d/ d/o o or concomitant m med di dications.
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